See more : Shandong Ruifeng Chemical Co., Ltd. (300243.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Kenvue Inc. (KVUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kenvue Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- U.S. Oil and Gas Plc (USOPY) Income Statement Analysis – Financial Results
- Ficha Inc. (4052.T) Income Statement Analysis – Financial Results
- Belships ASA (BELCO.OL) Income Statement Analysis – Financial Results
- Diebold Nixdorf, Incorporated (DBD.DE) Income Statement Analysis – Financial Results
- Medigene AG (0QGJ.L) Income Statement Analysis – Financial Results
Kenvue Inc. (KVUE)
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.44B | 14.95B | 15.05B | 14.47B | 14.32B |
| Cost of Revenue | 6.80B | 6.67B | 6.64B | 6.62B | 6.66B |
| Gross Profit | 8.64B | 8.29B | 8.42B | 7.85B | 7.66B |
| Gross Profit Ratio | 55.96% | 55.42% | 55.93% | 54.25% | 53.49% |
| Research & Development | 399.00M | 375.00M | 355.00M | 320.00M | 391.00M |
| General & Administrative | 4.33B | 4.28B | 4.02B | 3.73B | 3.94B |
| Selling & Marketing | 1.35B | 1.36B | 1.46B | 1.23B | 1.26B |
| SG&A | 5.68B | 5.63B | 5.48B | 4.96B | 5.20B |
| Other Expenses | 50.00M | 4.00M | 25.00M | 3.00M | 59.00M |
| Operating Expenses | 6.13B | 5.62B | 5.41B | 4.86B | 5.26B |
| Cost & Expenses | 12.93B | 12.28B | 12.04B | 11.48B | 11.93B |
| Interest Income | 108.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 358.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 627.00M | 644.00M | 731.00M | 746.00M | 709.00M |
| EBITDA | 3.18B | 3.64B | 3.87B | 3.79B | 3.28B |
| EBITDA Ratio | 20.56% | 22.39% | 25.61% | 53.51% | 25.98% |
| Operating Income | 2.51B | 2.68B | 2.92B | -979.00M | 1.85B |
| Operating Income Ratio | 16.27% | 17.89% | 19.40% | -6.77% | 12.89% |
| Total Other Income/Expenses | -322.00M | -38.00M | 5.00M | -37.00M | 274.00M |
| Income Before Tax | 2.19B | 2.64B | 2.93B | -1.02B | 2.12B |
| Income Before Tax Ratio | 14.18% | 17.64% | 19.43% | -7.02% | 14.80% |
| Income Tax Expense | 526.00M | 550.00M | 894.00M | -137.00M | 685.00M |
| Net Income | 1.66B | 2.06B | 2.08B | -879.00M | 1.44B |
| Net Income Ratio | 10.77% | 13.81% | 13.80% | -6.08% | 10.02% |
| EPS | 0.90 | 1.08 | 1.08 | -0.47 | 0.76 |
| EPS Diluted | 0.87 | 1.08 | 1.08 | -0.47 | 0.76 |
| Weighted Avg Shares Out | 1.85B | 1.91B | 1.89B | 1.89B | 1.89B |
| Weighted Avg Shares Out (Dil) | 1.92B | 1.91B | 1.89B | 1.89B | 1.89B |
53 August Dividend Kings: Buy 7, Watch 9 More
Kenvue Goes Boom - Now What?
The 7 Best Under $20 Stocks to Buy in August 2024
S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance
Kenvue News: Why Investors Are Loving KVUE Stock This Week
4 Dividend Aristocrats To Buy In August And More To Watch
Kenvue Is the S&P 500 Stock After Earnings. Here's Why.
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
Source: https://incomestatements.info
Category: Stock Reports